Concepedia

Jennifer A. Lockridge

JA

10

Publications

2.2K

Citations

10

H-Index

2003

Active since

Affiliations

Mirna Therapeutics (United States)(Current)

Novartis (Switzerland)

Cleveland Clinic

Jennifer A. Lockridge is an author at Mirna Therapeutics (United States) specializing in medicine, biochemistry, and pharmacotherapy.

Top concepts

Publications per year

2003–2017

10

Publications

10

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

Jennifer A. Lockridge, Lucinda Shaw, Karin S. Blanchard et al. · Nature Biotechnology · 2005 · 1.2K citations

, , +9

Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†

Karin S. Blanchard, Lucinda Shaw, Kristi Jensen et al. · Hepatology · 2005 · 290 citations · Full text

Virally delivered Channelrhodopsin-2 Safely and Effectively Restores Visual Function in Multiple Mouse Models of Blindness

M. Mehdi Doroudchi, Kenneth P. Greenberg, Jianwen Liu et al. · Molecular Therapy · 2011 · 275 citations · Full text

RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027

Peter K. Kaiser, R. C. Andrew Symons, Syed Mahmood Shah et al. · American Journal of Ophthalmology · 2010 · 188 citations

, , +2

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

David Weng, P. Masci, Susan F. Radka et al. · Molecular Cancer Therapeutics · 2005 · 75 citations · Full text

Rows per page

1–5 of 10